{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016016","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.918100+00:00","generated_at":"2026-06-24T02:11:36.434581+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cyclerion reports Q2 net loss $13.4M; positive CY6463 data in MELAS and CIAS studies","bullets":["Cash $30.3M at June 30, 2022; net loss $13.4M vs $16.2M year ago.","CY6463 showed improvements in biomarkers, cognitive performance, safety in MELAS and CIAS studies.","Appointed Steven E. Hyman, M.D. to Board of Directors effective July 25, 2022.","Enrollment ongoing in Phase 2a Alzheimer's disease with vascular pathology study; topline results expected 2023.","R&D expenses $10.2M, G&A $3.5M; both down YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016016","json":"https://secwatch.observer/filing/0000950170-22-016016.json","markdown":"https://secwatch.observer/filing/0000950170-22-016016.md","text":"https://secwatch.observer/filing/0000950170-22-016016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022016016/0000950170-22-016016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022016016/cycn-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:11:36.434581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}